ALNY Earnings & Financial Statements
Alnylam Pharmaceuticals, Inc.
$224.47
+$0.65(+0.29%)
34
Overall
20
Value
18
Tech
65
Quality
Market Cap
$30.04B
Volume
1.11M
52W Range
$197.81 - $495.55
Target Price
$377.39
ALNY earnings and financial statements: Alnylam Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ALNY Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844.29M |
| Cost of revenue | $681.87M | $306.51M | $268.22M | $168.82M | $140.14M |
| Operating income | $501.58M | -$176.88M | -$282.18M | -$785.07M | -$708.65M |
| EBITDA | $631.44M | -$178.85M | -$258.24M | -$929.94M | -$619.43M |
| Net income | $313.75M | -$278.16M | -$440.24M | -$1.13B | -$852.82M |
| EPS (diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B |
| Total liabilities | $4.18B | $4.17B | $4.05B | $3.70B | $3.06B |
| Shareholders’ equity | $789.18M | $67.09M | -$220.64M | -$158.22M | $588.20M |
| Cash and equivalents | $1.66B | $966.43M | $812.69M | $866.39M | $819.98M |
| Long-term debt | $1.23B | $1.25B | $1.26B | $1.28B | $957.04M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $524.08M | -$8.31M | $104.16M | -$541.27M | -$641.69M |
| Capital expenditure | -$58.70M | -$34.28M | -$62.21M | -$72.06M | -$76.37M |
| Free cash flow | $465.38M | -$42.59M | $41.95M | -$613.33M | -$718.07M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ALNY | $224.47 | +0.3% | 1.11M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Alnylam Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW